Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley; K. Papp; A. B. Gottlieb; G. G. Krueger; K. B. Gordon; D. Williams; J. Valdes; C. Setze; B. Strober

doi:10.1111/j.1468-3083.2012.04705.x

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley, K. Papp, A. B. Gottlieb, G. G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze, B. Strober

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

59 Citations (Scopus)

Original language	English
Pages (from-to)	1252-1261
Number of pages	10
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	27
Issue number	10
DOIs	https://doi.org/10.1111/j.1468-3083.2012.04705.x
Publication status	Published - Oct 2013

ASJC Scopus Subject Areas

Dermatology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1468-3083.2012.04705.x

Fingerprint

Dive into the research topics of 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis'. Together they form a unique fingerprint.

Cite this

Langley, R. G., Papp, K., Gottlieb, A. B., Krueger, G. G., Gordon, K. B., Williams, D., Valdes, J., Setze, C., & Strober, B. (2013). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 27(10), 1252-1261. https://doi.org/10.1111/j.1468-3083.2012.04705.x

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. / Langley, R. G.; Papp, K.; Gottlieb, A. B. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 27, No. 10, 10.2013, p. 1252-1261.

Research output: Contribution to journal › Article › peer-review

Langley, RG, Papp, K, Gottlieb, AB, Krueger, GG, Gordon, KB, Williams, D, Valdes, J, Setze, C & Strober, B 2013, 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis', Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 10, pp. 1252-1261. https://doi.org/10.1111/j.1468-3083.2012.04705.x

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 2013 Oct;27(10):1252-1261. doi: 10.1111/j.1468-3083.2012.04705.x

Langley, R. G. ; Papp, K. ; Gottlieb, A. B. et al. / Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. In: Journal of the European Academy of Dermatology and Venereology. 2013 ; Vol. 27, No. 10. pp. 1252-1261.

@article{f7ea7ea9cf004658b80e84d0970fa53d,

title = "Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis",

author = "Langley, {R. G.} and K. Papp and Gottlieb, {A. B.} and Krueger, {G. G.} and Gordon, {K. B.} and D. Williams and J. Valdes and C. Setze and B. Strober",

year = "2013",

month = oct,

doi = "10.1111/j.1468-3083.2012.04705.x",

language = "English",

volume = "27",

pages = "1252--1261",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

AU - Langley, R. G.

AU - Papp, K.

AU - Gottlieb, A. B.

AU - Krueger, G. G.

AU - Gordon, K. B.

AU - Williams, D.

AU - Valdes, J.

AU - Setze, C.

AU - Strober, B.

PY - 2013/10

Y1 - 2013/10

UR - http://www.scopus.com/inward/record.url?scp=84884900971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884900971&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2012.04705.x

DO - 10.1111/j.1468-3083.2012.04705.x

M3 - Article

C2 - 23157612

AN - SCOPUS:84884900971

SN - 0926-9959

VL - 27

SP - 1252

EP - 1261

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 10

ER -

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this